Annemarie Mj Wensing
Overview
Explore the profile of Annemarie Mj Wensing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steegen K, Moorhouse M, Wensing A, Venter W, Hans L
J Int AIDS Soc
. 2021 May;
24(5):e25706.
PMID: 33943000
Introduction: Dolutegravir has replaced efavirenz in most low- and middle-income countries, due to better tolerability and formidable resistance profile, but dolutegravir side effects suggest alternatives are needed. We evaluated doravirine...
2.
Hermans L, Steegen K, Ter Heine R, Schuurman R, Tempelman H, Moraba R, et al.
J Int AIDS Soc
. 2020 Jun;
23(6):e25501.
PMID: 32515898
Introduction: When protease inhibitor (PI)-based second-line ART fails, guidelines recommend drug resistance testing and individualized third-line treatment. However, PI-resistant viral strains are rare and drug resistance testing is costly. We...
3.
Bosman K, Wensing A, Pijning A, van Snippenberg W, van Ham P, de Jong D, et al.
J Int AIDS Soc
. 2018 Oct;
21(9):e25185.
PMID: 30375818
Introduction: The latent reservoir is the main barrier on the road to HIV cure, and clinical approaches towards eradication are often evaluated by their effect on proviral DNA. To ensure...
4.
Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver D, Albert J, et al.
Retrovirology
. 2012 Oct;
9:81.
PMID: 23031662
Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug...
5.
van Maarseveen N, Wensing A, De Jong D, Beilhartz G, Obikhod A, Tao S, et al.
Antivir Ther
. 2011 Oct;
16(7):1123-30.
PMID: 22024528
Background: HIV-HBV-coinfected individuals who need to be treated only for their HBV infection have limited therapeutic options, since most approved anti-HBV agents have a risk of selecting for drug-resistant HIV...
6.
Arends J, van Assen S, Stek C, Wensing A, Fransen J, Schellens I, et al.
Antivir Ther
. 2011 Oct;
16(7):979-88.
PMID: 22024513
Background: Despite a rising incidence of acute HCV in patients infected with HIV, the optimal therapeutic strategy (pegylated interferon-α [PEG-IFN-α] monotherapy or in combination with ribavirin) is still under debate....
7.
Hamers R, Wensing A, Back N, Arcilla M, Frissen J
Antivir Ther
. 2011 Feb;
16(1):115-8.
PMID: 21311115
We report a 33-year-old HIV type-1 (HIV-1)-infected male from Sierra Leone who harboured extensive drug resistance mutations to all nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs, including the multi-NRTI-resistance Q151M...
8.
Paraskevis D, Pybus O, Magiorkinis G, Hatzakis A, Wensing A, van de Vijver D, et al.
Retrovirology
. 2009 May;
6:49.
PMID: 19457244
Background: The prevalence and the origin of HIV-1 subtype B, the most prevalent circulating clade among the long-term residents in Europe, have been studied extensively. However the spatial diffusion of...
9.
Wensing A, Boucher C, van Kasteren M, Van Dijken P, Geelen S, Juttmann J
AIDS
. 2006 Jun;
20(10):1465-7.
PMID: 16791028
No abstract available.